



1 Supplemental

A




B



2
3
4
5
6
7
8
9


Supplemental Figure 1. VSP-1 and VSP-2 schematic and predicted gene networks (MRS). Cartoon of VSP-1 (A) and VSP-2 (B) from El Tor *V. cholerae* N16961 and gene network predictions from Correligy. Arrows indicate the highest partial correlation W_{ij} each gene has to another (ovals). Two arrows are presented pointing in opposing directions where the highest correlation W_{ij} is reciprocal between two genes. MRS = maximum relatedness subnetwork



10
11
12
13
14
15
16
17
18


Supplemental Figure 2. Complementation of various ig^{222} constructs to prevent AvcD induced cell filamentation.

Cell length distributions of Δig^{222} *V. cholerae* expressing pAvcD. All cell length distributions represent ~750-1000 cells measured per strain with summary statistics: mean (diamonds), median (horizontal black line), interquartile range (box), and data below and above the interquartile range (vertical lines). Different letters indicate significant differences at $p < 0.05$, according to Tukey's post-hoc test.



19
 20 **Supplemental Figure 3. AvcD C-terminal 6x Histidine fusion maintains the same activity as**
 21 **the WT AvcD enzyme and the presence of *avcI* does not reduce the abundance of AvcD.**
 22 **(A)** Representative images of WT *V. cholerae* and Δig^{222} cultures maintaining an empty vector
 23 plasmid (pVector1) or P_{tac} -inducible *avcD-6xHIS* plasmid (pAvcD^{6xHis}) grown in the presence of
 24 100 μ M IPTG for 2 h. Cells were stained with FM4-64 prior to imaging and performed in biological
 25 triplicate. **(B)** Representative coomassie stained PAGE gel (top) and matched anti-6x His antibody
 26 Western blot (bottom) of whole cell lysates normalized to total protein from *V. cholerae* WT and
 27 Δig^{222} cultures maintaining pVector1 or pAvcD^{6xHis}. Black triangles correspond to AvcD^{6xHis} (60.6
 28 kDa). Analysis was performed in biological triplicate and the relative signal intensity **(C.)** was the
 29 determined by comparing the intensities of AvcD^{6xHIS} from paired WT and Δig^{222} lysates probed
 30 on the same blots.

31
 32
 33
 34
 35
 36




37
 38 **Supplemental Figure 4. AvcD-AvcI complex formation in solution and Denaturing urea**
 39 **PAGE analysis of Avcl and Avcl-RC.**
 40 (A) AvcD forms a complex with Avcl in an AvcD concentration-dependent manner as determined
 41 by EMSA. Trace quantities of Avcl reverse complement (Avcl-RC) binding to AvcD in a non-
 42 specific manner is observed. (B) Avcl and Avcl-RC run at essentially equivalent molecular weights
 43 on a 7 M urea denaturing PAGE. Low range ssRNA ladder (NEB).
 44
 45
 46
 47
 48
 49

V. cholerae	MFTMKSSAKKILSTVPS--PTKSNSSSSNDLQKRILERRSRELVIGLCGAIGSGVKALKESLVSSLETYGVEVDIRISKIIESEKTQ--T--SLDGLSAFKRYNRLQDLGNSLRETHK	113
V. parahaemolyticus	---MGKSSTATKLPQLQ--SVSTSSSTEDIQKRIEQERRSQELIIGLCGAIGSGVKALKDNLIHSLSSGYQVQHIRISNIIAEKTN--I--VIDNIIHAERYITLQDKGDELRESEK	110
P. mirabilis	---MGNPAKVITITNNLS--DVNFDSDFDKVESKIKERHSNLIILALCGTAVSGVRKLESLIEQFENFNKVKHIRISDLIAEQNESPO--KIKNLSGYSRYEKLQDLGDELREKNT	112
E. coli	---MA----IALKKEVQKKGSLSDNSNSPEMQTIIITRQSPDLFVIGLCPGAGCGKTKVNSLVKVAKSNHYDVVHRIISDLMDPLDLYFEKKVIEENDVLNKERHIRMKQLANGLRHRYK	112
	* * * * * * * * * * * *	
V. cholerae	SS-ILAACAIEIALERTLICQNEIDETSEENDNEPSLIKTKKIAVYIDQLKHPDEIKF LRSVYPRNFYL IGLIRTEGERRLNLEEEKISPSEITL MRRDRKD-VSHGQQVEKSLFHA	231
V. parahaemolyticus	TS-ILAACAIIEI AVARTIFCQDEIEE-----DDQASVITTKKIAYVLDQLKHPDEVKLLRSVYPRNFYLLGLIRTEKERRLNLEEEKMSLQEI DELIRDRKG-VDHGQQVEKTLHNA	223
P. mirabilis	NN-ICAQLAIRRIINWRHRTYGT ELKE-----NESP KHTKLTDKVYIIDQLKHPAEVGLFRTVYKNNFYLLGLLRNVNERERNLRADGLDSEIKLLINRDRKNSASYGQVEDTLQLS	226
E. coli	KKELLAEAAITYIKSOK-----VKK-----EOKSVKTKTIVYIIDQLKRP EIEELRIIYQHHFYLLIGIVRDP EHTVRNLKEDDSSL EDIYHIINVDKSDODFGQRTSKAILDS	216
	.. : * * * * * : : : : * * * * * * * * *	
V. cholerae	DYFIHNHNQKQHLKDSVERFIKLVHGINGISPTIDEIGMHAAYSAAALRSACL SRQVGAAILDNQGNIIITGCNDVPSFGGGLYNSNS-LADFRCV-HTGRCSNDKHKDILKEEITDILK	349
V. parahaemolyticus	DYFIHNHNHNSQLLEKSVDRFIKLVHGVNITPTIDEIGMHAASHASLRSACL SRQVGAAITDEHGGVISTGCNDVPSFNGGLYNSNS-STD FRCV-HRGCQNDKHKALLKEEIRDILS	341
P. mirabilis	DYFI RNIEQLS-EINKSVNRFISL I HGVHITPTKDEIGMFTAYHSSLRACL SRQVGACIVDDEGNLSTGCNDVPKFKGGLYNAES-VSDNRCH-NVGRCSNDLHKSMLRKHQI IDILQ	343
E. coli	DVFIKNNQSQKNNLEKKINRFGLIHGQGLTP IA EKG MYSAYAASLQSACL SRQVGAALLDDEGNL LAVGKNDVPKSGGGLYISDDGDNDRHC VYKSGKYNIA TKLKIKKR IADILI	336
	* * * * * * * * * * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * * : * * * * *	
V. cholerae	KSITNTLE-----LKEIVNQITSEKIKTLIEYSRAVHAEMDSLIALARN NKETSVDKTL YVTTYPCHNCARHIVAAGIKKVVVYEPYKSLAMKLHDDSIDNADA-KN	453
V. parahaemolyticus	KELNNEVL-----LNTLTKITSGTKIKSLIEYSRAVHAEMDAIVALARN NKESAVGKTL FATTYPCHNCARHIVAAGIKRVVYIEPYKSLAMKLHDDSIDTDSGE--SE	444
P. mirabilis	DESIDD-----AENLASKIMNNTKAKYII EYSRAIHAEMDAISMLARN TSVGTVDKIMHYCTTYPCHNCARHIVAAGIKKVVVYIEPYKSLARLDHDAICHDDMSSE	446
E. coli	DELKNNIGSDSNLDFLFKKISNNIADIADVYSKISSVM EYSRSIHAEMDVIITMARK SSEGKGTLYTTTYPCHNCARHIVSSGMKVIYIEPFOKSLALDLHDDAITTTED--PS	454
	.. : * * * * * * * * * * *	
V. cholerae	KVCLFPFEGVSSRRYEVFFQMHGDRKDDKTGKVLNINIQDSYHADSEFLDNYAEMAKIAQSVNALLNVPSS EEESTQD	532
V. parahaemolyticus	KVKLSPFEGVSPRRFEAFFRSNGNRKDD-DGRVIKIKVHDSYHADSEFIDNYP EMEAKVAQSVSDFTKQV EATI-E-	520
P. mirabilis	KVLFANFEGVSPHRYSSFFKYHSARKDK-DGRVLNQKVITAKQVPTGLDSYFYDEAKTVQDVLNRLGEERS-----	517
E. coli	RVIFSKFEGVAPRRYKFFMP TDERKDEV TGEAYS FNVKYKRHIDVQFLDSYRTYEDIVAQRFLKDVAKVEPKQDDL I-	532
	: * : * * * : * . * * . * : * : * * * * * * * * * : * : * * * * * * * * * : * : * * * * * * * * * : * : * * * * * * * * * : * : * * * * * * * * *	

50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85

Supplemental Figure 5. ClustalW multiple sequence alignment of Avcd homologs show conservation of likely active site residues explored in this study.

Amino acid alignment of the *V. cholerae* Avcd and three homologs using EMBL-EBI ClustalW⁴². “*” indicates 100% identity, “:” indicates >75%, and “.” Indicates >50% similarity. Black triangles indicate conserved residues in *V. cholerae* Avcd targeted for site-directed mutagenesis.



86

87 **Supplemental Figure 6. Nucleotide multiple sequence alignment of Avcl and homologs.**
 88 Nucleotide alignment of *V. cholerae* Avcl and three homologs using LocARNA⁴³. The average
 89 secondary structure is indicated in dot-bracket notation (top). Consensus identities are correlated
 90 with the height of the bars below the corresponding nucleotide. Compatible base pairs are colored
 91 according to the number of different types C-G (1), G-C (2), A-U (3), U-A (4), G-U (5) or U-G (6)
 92 of compatible base pairs in the corresponding columns. The color saturation decreases with the
 93 number of incompatible base pairs.

94

95

96


97

98

99

100

101



102
103
104
105
106
107
108
109
110


Supplemental Figure 7. Cross-species inhibition of *avcD* and *avcI* homologs.

Cell length distributions of *E. coli* co-expressing various combinations of P_{tac}-inducible plasmids encoding homologs of *avcD* and *avcI*. All cell length distributions represent ~1000-3000 cells measured per strain with summary statistics: mean (diamonds), median (horizontal black line), interquartile range (box), and data below and above the interquartile range (vertical lines). Different letters indicate significant differences at $p < 0.05$, according to Tukey's post-hoc test. VC = *Vibrio cholerae*, VP = *Vibrio parahaemolyticus*, PM = *Proteus mirabilis*, ETEC = *E. coli* ETEC .

A



B




111

112 **Supplemental Figure 8. Phylogenetic analysis and domain architectures of the six AvcD**
 113 **query proteins.**

114 (A) Phylogenetic tree of AvcD homologs from representative phyla across the tree of life. Stars
 115 indicate the six proteobacterial starting points for the homology search, as well as the eukaryotic
 116 *Saccharomyces cerevisiae dcd1* (triangle), explored in Fig. S9. (B) Domain architecture and
 117 secondary structure predictions for the six proteobacterial starting points (query proteins) were
 118 predicted using InterProScan⁴⁹ (Methods). Results from six main analyses are shown here for the
 119 query proteins: Gene3D (including CATH structure database), Pfam, ProSiteProfiles, PANTHER,

120 and SUPERFAMILY protein domain profile databases, and MobiDBLite for disorder prediction.
121 No transmembrane regions (using TMHMM) or membrane/extracellular localization were
122 predicted for any of the proteins (using Phobius); hence not shown. Numbers (bottom) indicate
123 the amino acid position of predicted domains and features.
124



126

127

128

129

130



131

132

133

Supplemental Figure 9. AvcD homolog from *Saccharomyces cerevisiae*, Dcd1, also induces filamentation in *E. coli*.


Cell length distributions of *E. coli* expressing pAvcD, a P_{tac}-inducible plasmid encoding *dcd1* from *S. cerevisiae* (pDcd1^{Sc}), or pVector1. All cell length distributions represent ~1000-3000 cells measured per strain with summary statistics: mean (diamonds), median (horizontal black line), interquartile range (box), and data below and above the interquartile range (vertical lines). Different letters indicate significant differences at $p < 0.05$, according to Tukey's post-hoc test.




134
135
136
137
138
139
140
141
142
143
144
145
146

Supplemental Figure 10. Mutations in conserved residues of AvcD do not affect the stability of the protein.

(A) Phyre2¹² predicted structure of AvcD from *V. cholerae* El Tor. Insets highlight conserved residues of the PLN (top) and DCD (bottom) domains selected for mutagenesis. (B) Representative Coomassie stained gel (top) and anti-6x His antibody Western blot (bottom) of whole cell lysates from *E. coli* BL21(DE3) cells maintaining an empty vector (pVector^{6xHis}), inducible C-terminal 6x histidine tagged *avcD* (WT) or *avcD* variants (S52K, D162A + Q163A, E384A, and C411A + C414A) grown in the presence of 1 mM IPTG for 3 h. Sample inputs were normalized by culture OD₆₀₀ and resolved by SDS-PAGE. Three biological replicates of each strain were analyzed with similar results. Black triangles correspond to the predicted molecular weight of the AvcD tagged fusions (60.6 kDa). M = molecular weight marker.




147
 148 **Supplemental Figure 11. AvcD activity induces TLD-phenotype.**
 149 (A) *V. cholerae* mutant expressing the indicated AvcD variants. *ori/ter* ratios of Chromosome 1 in
 150 Δig^{222} *V. cholerae* strains expressing the indicated pAvcD construct and quantified using qRT-
 151 PCR. Each bar represents the mean \pm SEM, $n=3$. Different letters indicate significant differences
 152 ($n=3$) at $p < 0.05$, according to Tukey's post-hoc test. (B) Representative images of Δig^{222} cultures
 153 maintaining an empty vector plasmid pVector 1 or pAvcD grown in the presence of 100 μ M IPTG
 154 for 8 h. Cells were stained with FM4-64 prior to imaging and performed in biological triplicate. (C)
 155 Relative difference in *avcD* expression between Δig^{222} and WT *V. cholerae* at three different
 156 growth phases using qRT-PCR and an endogenous *gyrA* control. Data represent the mean \pm
 157 SEM of three biological replicates.
 158
 159



160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184

Supplemental Figure 12. Cessation of global translation, by treatment with spectinomycin, does not liberate AvcD enzymatic activity.

Intracellular concentration of dCTP (A), dCMP (B), dUTP (C), and dUMP (D) of WT and $\Delta avcD$ *V. cholerae* during spectinomycin treatment (200 $\mu\text{g}/\text{mL}$) measured by UPLC-MS/MS. Data represent the mean \pm SEM of three biological replicate cultures. No statistically significant differences in nucleotide concentrations were observed between strains at any time point as determined by Two-way ANOVA with Šídák's multiple-comparison test.




185
 186 **Supplemental Figure 13. Ectopic expression of DncV and AvcD does not lead to**
 187 **filamentation in the $\Delta capV$ mutant of *V. cholerae*.**

188 Cell length distributions measured from three biological replicates of $\Delta capV$ *V. cholerae* cultures
 189 co-expressing either two empty vectors, pDncV and an empty vector, pAvcD and an empty vector,
 190 or pDncV and pAvcD grown in the presence of 100 μM IPTG for 8 h. Distributions represent
 191 ~1200-1700 cells measured per strain. Different letters indicate significant differences at $p < 0.05$,
 192 according to Tukey's post-hoc test.

193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211

AvclD systems	Coliphages									
	Myoviridae			Podoviridae		Siphoviridae				Microviridae
	T2	T4	T6	T3	T7	λ-vir	T5	SECΦ18	SECΦ27	SECΦ17
VC	2	2	2	8	1	1	2	1	1	1
VP	1	1	4	64	1	1	64	8	1	1
PM	1	8	1	1	1	1	1	1	1	1
ETEC	1	1	1	64	1	1	1	4	4	4



212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253

Supplemental Figure 14. Summary of Figure 4A. Data are the mean of the three biological replicates rounded to the nearest fold of plaque reduction relative to empty vector control. VC = *Vibrio cholerae*, VP = *Vibrio parahaemolyticus*, PM = *Proteus mirabilis*, ETEC = *E. coli* ETEC.

Supplementary Table 1. Bacterial strains and phages used in this study.

Strains	Name in this Study	Relevant Characteristics	Source or reference
<i>E. coli</i>			
DH10b		<i>F-mcrA</i> Δ (<i>mrr-hsdRMS-mcrBC</i>) Φ 80 <i>lacZ</i> Δ M15 Δ <i>lacX74 recA1 endA1 araD139Δ(<i>ara, leu</i>)7697 <i>galU galK</i> <i>lrpsL nupG</i></i>	ThermoFisher Scientific
BW29427		<i>RP4-2</i> (<i>TetSkan1360::FRT</i>), <i>thrB1004, lacZ58</i> (M15), Δ <i>dapA1341::[erm pir⁺]</i> , <i>rpsL</i> (<i>strR</i>), <i>thi-</i> , <i>hsdS-</i> , <i>pro-</i>	Lab Stock
BL21(DE3)		<i>F- ompT hsdSB</i> (<i>rB -mB +</i>) <i>gal dcm</i> (DE3)	Lab Stock
MG1655		<i>F-lambda- ilvG- rfb-50 rph-1</i>	Lab Stock
078:H11 H10407 (ETEC)	ETEC	Wild type	41
<i>V. cholerae</i>			
C6706str2	WT and VC	Wild type O1 EI Tor; Sm ^R	30
CR01	Δ VSP-1	O1 EI Tor Δ VSP-1	This study
CR02	Δ VSP-2	O1 EI Tor Δ VSP-2	This study
CR03	Δ VSP-1/2	O1 EI Tor Δ VSP-1/2	This study
BYH206	Δ <i>ig</i> ²²²	O1 EI Tor Δ <i>ig</i> ²²² between <i>vc0175-vc0176</i> position in N16961 chromosome I [177,230-177,008]	This study
BYH207	Δ <i>vc0176</i>	O1 EI Tor Δ <i>vc0176</i>	This study
GS05	Δ <i>avcD</i>	O1 EI Tor Δ <i>avcD</i>	This study
WLN5105	Δ <i>capV</i>	O1 EI Tor Δ <i>capV</i>	8
<i>V. parahaemolyticus</i>			
O1:Kuk str. FDA_R31	VP	Wild type	39
<i>P. mirabilis</i>			
AR379	PM	Wild type	40
<i>S. cerevisiae</i>			
yMK839	Sc	<i>MATa leu2-3 trp1 ura3-52</i>	11
Phages			
T2	T2	Wild type	ATCC
T3	T3	Wild type	ATCC
T4	T4	Wild type	ATCC
T5	T5	Wild type	ATCC
T6	T6	Wild type	ATCC
T7	T7	Wild type	ATCC
λ virulent	λ vir	Wild type	Gift from M. Laub
SEC ϕ 17	SEC ϕ 17	Wild type	Gift from M. Laub
SEC ϕ 18	SEC ϕ 18	Wild type	Gift from M. Laub
SEC ϕ 27	SEC ϕ 27	Wild type	Gift from M. Laub

258 **Supplementary Table 2: Plasmids Descriptions**

Plasmids	Name in this Manuscript	Relevant characteristics	Source or Reference
pEVS141	pVector1	pEVS143 without P _{tac} ; Km ^r	34
pEVS143		Broad-host range P _{tac} overexpression vector; Km ^r	32
pMMB67EH	pVector2	Broad-host range P _{tac} overexpression vector; Amp ^r	33
pKAS32		Suicide vector for mutant construction, Amp ^r	31
pET28b	pVector ^{6xHis}	T7 promoter; Km ^r	Novagen
pBRP353	pDncV	pMMB67EH:: <i>dncV</i> ; Amp ^r	8
pCMW204	pAvcD	pEVS143:: <i>avcD</i> ; Km ^r	This study
pGBS87	pAvcD/pAvcD ^{VC}	pMMB67EH:: <i>avcD</i> ; Amp ^r	This study
pGBS65	pAvcD ^{6xHis}	pET28b:: <i>avcD-6xHis C-term</i> ; Km ^r (*only* in <i>E. coli</i> BL21(DE3))	This study
pGBS98	pAvcD ^{6xHis}	pEVS143:: <i>avcD-6xHis C-term</i> ; Km ^r (*only* in <i>V. cholerae</i>)	This study
pAvcD ⁴⁻⁵³²		pET28b:: <i>avcD^{4-532}-6xHis N-term}</i> ; Km ^r	This study
pGBS71	pAvcD ^{E384A}	pEVS143:: <i>avcD-E384A</i> ; Km ^r	This study
pGBS82	pAvcD ^{E384A}	pET28b:: <i>avcD-E384A-6xHis C-term</i> ; Km ^r (*only* for in vitro and western blot)	This study
pGBS81	pAvcD ^{C411A+C414A}	pEVS143:: <i>avcD-C411A+C414A</i> ; Km ^r	This study
pGBS75	pAvcD ^{C411A+C414A}	pET28b:: <i>avcD-C411A+C414A-6xHis C-term</i> ; Km ^r	This study
pGBS103	pAvcD ^{S52K}	pEVS143:: <i>avcD-S52K</i> ; Km ^r	This study
pGBS114	pAvcD ^{S52K}	pET28b:: <i>avcD-S52K-6xHis C-term</i> ; Km ^r	This study
pGBS106	pAvcD ^{D162A+Q163A}	pEVS143:: <i>avcD-D162A+Q163A</i> ; Km ^r	This study
pGBS116	pAvcD ^{D162A+Q163A}	pET28b:: <i>avcD-D162A+Q163A-6xHis C-term</i> ; Km ^r	This study
pGBS80	pI _g ²²²	pEVS143:: <i>Ig²²²</i> , (position in N16961 chromosome I [177,230-177,008]); Km ^r	This study
pGBS108	pI _g ^{222-STOP}	pEVS143:: <i>Ig^{222}-1C>T, 2T>A}</i> ; Km ^r	This study
pGBS110	pAvcl	pEVS143:: <i>avcl</i> (position in N16961 chromosome I [177,181-177,008]); Km ^r	This study
pAW01	pAvcl ^{RBS-less}	pEVS143:: <i>avcl</i> without RBS; Km ^r	This study
pGBS111	pAvcl ^{STOP}	pEVS143:: <i>avcl-1A>T, 2T>A, 3G>A</i> ; Km ^r	This study
pGBS118	pAvcl ^{InteriorSTOP}	pEVS143:: <i>avcl-17A>T, 18T>A, 19G>A</i> ; Km ^r	This study
pBYH49	pAvcl ⁴⁹⁻¹⁸⁶	pEVS143:: <i>Ig²²² truncation (49-186 NT)</i> ; Km ^r	This study
pBYH52	pAvcl ⁴⁹⁻²⁰⁴	pEVS143:: <i>Ig²²² truncation (49-204 NT)</i> ; Km ^r	This study
pBYH53	pAvcl ⁴⁹⁻²¹⁴	pEVS143:: <i>Ig²²² truncation (49-214 NT)</i> ; Km ^r	This study

pBYH54	pAvcl ⁴⁹⁻²¹⁸	pEVS143:: <i>Ig</i> ²²² truncation (49-218 NT); Km ^r	This study
pBYH55	pAvcl ⁶⁶⁻²²²	pEVS143:: <i>Ig</i> ²²² truncation (66-222 NT); Km ^r	This study
pBYH56	pAvcl ⁸⁶⁻²²²	pEVS143:: <i>Ig</i> ²²² truncation (86-222 NT); Km ^r	This study
pBYH57	pAvcl ¹²³⁻²²²	pEVS143:: <i>Ig</i> ²²² truncation (123-222 NT); Km ^r	This study
pGBS124	pAvcD ^{ETEC}	pEVS143:: <i>avcD</i> from <i>Escherichia coli</i> O78:H11 H10407 (ETEC); Km ^r (*only* for mass spec experiment)	This study
pGBS125	pAvcl ^{ETEC}	pEVS143:: <i>avcl</i> from <i>E. coli</i> O78:H11 H10407 (ETEC); Km ^r	This study
pGBS126	pAvcD ^{ETEC}	pMMB67EH:: <i>avcD</i> from ETEC; Amp ^r	This study
pAW07	pAvcl ^{VP}	pEVS143:: <i>avcl</i> from <i>V. parahaemolyticus</i> O1:Kuk str. FDA_R31; Km ^r	This study
pAW06	pAvcD ^{VP}	pMMB67EH:: <i>avcD</i> from <i>V. parahaemolyticus</i> O1:Kuk str. FDA_R31; Amp ^r	This study
pAW02	pAvcl ^{PM}	pEVS143:: <i>avcl</i> from <i>P. mirabilis</i> AR379; Km ^r	This study
pAW04	pAvcD ^{PM}	pMMB67EH:: <i>avcD</i> from <i>P. mirabilis</i> AR379; Amp ^r	This study
pBRP15		pMMB67EH without P _{tac} ; Amp ^r	This study
pBYH64		pBRP15:: <i>avcl-avcD</i> operon with its upstream intergenic region position in <i>V. cholerae</i> N16961 [177,759-176,932]; Amp ^r	This study
pBYH67		pBRP15:: <i>avcl-avcD</i> operon with its upstream intergenic region position in <i>V. parahaemolyticus</i> O1:Kuk str. FDA_R31 (CP006004) [468,152-466,174]; Amp ^r	This study
pBYH65		pBRP15:: <i>avcl-avcD</i> operon with its upstream intergenic region position in <i>P. mirabilis</i> AR379 (NZ_CP029133), [3,698,504-3,700,828]; Amp ^r	This study
pBYH63		pBRP15:: <i>avcl-avcD</i> operon with its upstream intergenic region position in ETEC (NC_017723.1), [2,280-4,414]; Amp ^r	This study
pBYH69		pEVS143:: <i>dcd1</i> from <i>Saccharomyces cerevisiae</i> ; Km ^r	This study
pBYH81	pAvcID ^{VP-avcDS47K}	pBYH67:: <i>avcD</i> -S47K; Amp ^r	This study
pBYH82	pAvcID ^{VP-avcDE376K}	pBYH67:: <i>avcD</i> -E376K; Amp ^r	This study
pBYH83	pAvcID ^{VP-avcDS47K+E376K}	pBYH67:: <i>avcD</i> -S47K+E376K; Amp ^r	This study
pCRR01		Deletion construct for ΔVSP-1, Amp ^r	This study
pCRR02		Deletion construct for ΔVSP-2, Amp ^r	This study
pBYH36		Deletion construct for Δ <i>Ig</i> ²²² , Amp ^r	This study
pBYH37		Deletion construct for Δ <i>vc0176</i> , Amp ^r	This study
pGBS88		Deletion construct for Δ <i>avcD</i> , Amp ^r	This study

CMW3165	<i>avcD</i> ^{ETEC} F BamHI (pMMB67EH-AvcD ^{ETEC})	CCTGCAGGTCGACTCTAGAGTTAAATCAAGTCA TCTTGTTTTGG	This study
CMW3166	<i>avc</i> ^{ETEC} F EcoRI + RBS (pEVS143-AvcI ^{ETEC})	ACAGCCTCGACAGGCCTAGGAGGAGCTAAGGA AGCTAAAATGTCAAACCAATTAACCG	This study
CMW3167	<i>avc</i> ^{ETEC} F BamHI (pEVS143-AvcI ^{ETEC})	GCTTGCTCAATCAATCACCGCTAATCAAGTATTA TTTCTTTCTTTAGTATTTTTATC	This study
CMW3180	<i>avc</i> ^{VP} F EcoRI + RBS (pEVS143-AvcI ^{VP})	ACAGCCTCGACAGGCCTAGGAGGAGCTAAGGA AGCTAAAATGGTTACAAATTTAAATG	This study
CMW3181	<i>avc</i> ^{VP} R BamHI (pEVS143-AvcI ^{VP})	GCTTGCTCAATCAATCACCGTTACCAACGAATTT TCTGTGCGGCTCTTAAAAG	This study
CMW3184	<i>avcD</i> ^{VP} F EcoRI + RBS (pMMB67EH-AvcD ^{VP})	CAATTTACACAGGAAACAGAGGAGCTAAGGAA GCTAAAATGGGAAAATCCTCTA	This study
CMW3185	<i>avcD</i> ^{VP} R BamHI (pMMB67EH-AvcD ^{VP})	CCTGCAGGTCGACTCTAGAGTTATTCAATAGTG GCTTCTACTTGTGGCTTTGTGAATG	This study
CMW3189	<i>avcI</i> F EcoRI (pEVS143-AvcI)	ACAGCCTCGACAGGCCTAGGATGATTACAAGCA TTCATGAATATAGAAAACGCTTC	This study
CMW3192	<i>avc</i> ^{PM} F EcoRI + RBS (pEVS143-AvcO ^{PM})	ACAGCCTCGACAGGCCTAGGAGGAGCTAAGGA AGCTAAAATGAACGTTCAAC	This study
CMW3193	<i>avc</i> ^{PM} R BamHI (pEVS143-AvcI ^{PM})	GCTTGCTCAATCAATCACCGTTACCAATCTAAC GTGTCTGCTACAGCTGC	This study
CMW3196	<i>avcD</i> ^{VP} F EcoRI + RBS (pMMB67EH-AvcD ^{PM})	CAATTTACACAGGAAACAGAGGAGCTAAGGAA GCTAAAATGGGTAATCC	This study
CMW3197	<i>avcD</i> ^{VP} R BamHI (pMMB67EH-AvcD ^{PM})	CCTGCAGGTCGACTCTAGAGTTAACTTCTCTCT TCACCTAAACGAAGATTTAC	This study
CMW3200	<i>avc</i> ⁴⁹⁻²⁰⁴ R BamHI (pEVS143-AvcI ⁴⁹⁻²⁰⁴)	GCTTGCTCAATCAATCACCGTGCAGCACGCAAA AGATTG	This study
CMW3201	<i>avc</i> ⁴⁹⁻²¹⁴ R BamHI (pEVS143-AvcI ⁴⁹⁻²¹⁴)	GCTTGCTCAATCAATCACCGGGATTTTTTGTGC AGCAC	This study
CMW3202	<i>avc</i> ⁴⁹⁻²¹⁸ R BamHI (pEVS143-AvcI ⁴⁹⁻²¹⁸)	GCTTGCTCAATCAATCACCGCAATGGATTTTTTG TGCAGCACGCAAAAAGA	This study
CMW3203	<i>avc</i> ⁶⁶⁻²²² F EcoRI + RBS (pEVS143-AvcI ⁶⁶⁻²²²)	ACAGCCTCGACAGGCCTAGGAGGAGCTAAGGA AGCTAAAGAATATAGAAACG	This study
CMW3204	<i>avc</i> ⁸⁶⁻²²² F EcoRI + RBS (pEVS143-AvcI ⁸⁶⁻²²²)	ACAGCCTCGACAGGCCTAGGAGGAGCTAAGGA AGCTAAAATAGCGACAAAAAC	This study
CMW3205	<i>avc</i> ¹²³⁻²²² F EcoRI + RBS (pEVS143-AvcI ¹²³⁻²²²)	ACAGCCTCGACAGGCCTAGGAGGAGCTAAGGA AGCTAAAAGACACTAGCG	This study
CMW3306	<i>avcI-avcD</i> w/ upstream intergenic regions from <i>V. cholerae</i> F EcoRI (pAvcI-AvcD ^{VC})	CGGGAAACCTGTCTGTGCCAGCTAGTCTTGAT GCTCTC	This study
CMW3307	<i>avcI-avcD</i> w/ upstream intergenic	CCTGCAGGTCGACTCTAGAGATAGAGACACTAT ATTTAGTGTTTTAATTAAC	This study

	regions from <i>V. cholerae</i> R BamHI (pAvcl-AvcD ^{VC})		
CMW3308	<i>avcl-avcD</i> w/ upstream intergenic regions from ETEC F EcoRI (pAvcl-AvcD ^{ETEC})	CGGGAAACCTGTCGTGCCAGTTAAATCAAGTCA TCTTGT TTTGGTTC	This study
CMW3309	<i>avcl-avcD</i> w/ upstream intergenic regions from ETEC R BamHI (pAvcl-AvcD ^{ETEC})	CCTGCAGGTGCGACTCTAGAGAGGCTCCGCTGA GAAAAAATTC	This study
CMW3310	<i>avcl-avcD</i> w/ upstream intergenic regions from <i>P. mirabilis</i> F EcoRI (pAvcl-AvcD ^{PM})	CGGGAAACCTGTCGTGCCAGTTAACTTCTCTCT TCACCTAAAC	This study
CMW3311	<i>avcl-avcD</i> w/ upstream intergenic regions from <i>P. mirabilis</i> R BamHI (pAvcl-AvcD ^{PM})	CCTGCAGGTGCGACTCTAGAGTGCTTTAACTCCT AAAGG	This study
CMW3312	<i>avcl-avcD</i> w/ upstream intergenic regions from <i>V. parahaemolyticus</i> F EcoRI (pAvcl-AvcD ^{VP})	CGGGAAACCTGTCGTGCCAGTTATTCAATAGTG GCTTCTAC	This study
CMW3313	<i>avcl-avcD</i> w/ upstream intergenic regions from <i>V. parahaemolyticus</i> R BamHI (pAvcl-AvcD ^{VP})	TGCCTGCAGGTGCGACTCTAGAGTCACTTTGCTG ATTTAAGCAGAT	This study
CMW3335	<i>dcd1^{Sc}</i> F EcoRI (pEVS143-Dcd1)	ACAGCCTCGACAGGCCTAGGAGGAGCTAAGGA AGCTAAAATGTTAATTGGTGTAAG	This study
CMW3336	<i>dcd1^{Sc}</i> R BamHI (pEVS143-Dcd1)	GCTTGCTCAATCAATCACCGTTAAATCATCACAA TTCTTGGTTC	This study
EWAvcDFwd	<i>avcD⁴⁻⁵³²</i> F NdeI (pAvcD ⁴⁻⁵³²) For protein purification	GTGCCGCGCGGCAGCCATATGAATAAGTCCTC CGCAA	This study
EWAvcDrev	<i>avcD⁴⁻⁵³²</i> R XhoI (pAvcD ⁴⁻⁵³²) For protein purification	TGGTGGTGGTGGTGGTGCTTAGTCTTGGATGCT CTCTTCTT	This study
Site-directed Mutagenesis			
CMW3011	<i>avcD</i> (E384A) F (pEVS143-AvcD ^{E384A} & pET28b-AvcD ^{E384A})	CAAGAGCGGTTTCATGCTGCAATGGATTCTCTTA TAGC	This study
CMW3012	<i>avcD</i> (E384A) R (pEVS143-AvcD ^{E384A} & pET28b-AvcD ^{E384A})	GCTATAAGAGAATCCATTGCAGCATGAACCGCT CTTG	This study

CMW3013	<i>avcD</i> (C411A + C414A) F (pEVS143-AvcD ^{C411A+C414A})	TATATGTTACGACATATCCGGCTCACAAACGCTG CGCGACACATCGTTGCTG	This study
CMW3014	<i>avcD</i> (C411A + C414A) R (pEVS143-AvcD ^{C411A+C414A})	CAGCAACGATGTGTGCGCGCAGCGTTGTGAGCC GGATATGTGCGTAACATATA	This study
CMW3021	<i>avcD</i> (K55A) F (pEVS143-AvcD ^{K55A})	GCTATTGGCTCTGGTGTAGCGGCATTAAAAGAG AGTTTAGTTAGTTCTCTTGAGACATAT	This study
CMW3022	<i>avcD</i> (K55A) R (pEVS143-AvcD ^{K55A})	ATATGTCTCAAGAGAATACTAACTCTCTTTT AATGCCGCTACACCAGAGCCAATAGC	This study
CMW3104	<i>avcD</i> (D162A + Q163A) F (pEVS143-AvcD ^{D162A+Q163A})	CGCATACATCATCGCGGCGTTAAAGCACCCCTGA TGAAATCAAATTCC	This study
CMW3105	<i>avcD</i> (D162A + Q163A) R (pEVS143-AvcD ^{Q162A+Q163A})	GGAATTTGATTTTCATCAGGGTGCTTTAACGCCG CGATGATGTATGCG	This study
CMW3110	<i>avcD</i> (S52K) F (pEVS143-AvcD ^{S52K})	CCTCTGTGGGGCTATTGGCAAAGGTGTAAAGG CATTAAAAGAGAG	This study
CMW3111	<i>avcD</i> (S52K) R (pEVS143-AvcD ^{S52K})	CTCTCTTTTAATGCCTTTACACCTTTGCCAATAG CCCCACAGAGG	This study
CMW3112	<i>avcD</i> (S52P) F (pEVS143-AvcD ^{S52P})	CCTCTGTGGGGCTATTGGCCCCGGGTGTAAAGG CATTAAAAGAGAG	This study
CMW3113	<i>avcD</i> (S52P) R (pEVS143-AvcD ^{S52P})	CTCTCTTTTAATGCCTTTACACCCGGGCCAATA GCCCCACAGAGG	This study
CMW3114	<i>avcD</i> (S52W) F (pEVS143-AvcD ^{S52W})	CCTCTGTGGGGCTATTGGCTGGGGTGTAAAGG CATTAAAAGAGAG	This study
CMW3115	<i>avcD</i> (S52K) R (pEVS143-AvcD ^{S52W})	CTCTCTTTTAATGCCTTTACACCCCAGCCAATAG CCCCACAGAGG	This study
CMW3118	<i>avcI</i> (interior alternative frame stop) F (pEVS143-AvcI17A>T, 18T>A, 19G>A)	AAGGAAGCTAAAATGATTACAAGCATTCTAAAAT ATAGAAACGCTTCTAATAGCG	This study
CMW3119	<i>avcI</i> (interior alternative frame stop) R (pEVS143-AvcI17A>T, 18T>A, 19G>A)	CGCTATTAGAAGCGTTTCTATATTTTAGAATGCT TGTAATCATTTTAGCTTCCTT	This study
CMW3448	<i>avcD</i> ^{VP} (S47K) F	ATTGGTCTTTGTGGAGCTATAGGCAAGGGTGTG AAAGCACTAAAAGATAAC	This study
CMW3449	<i>avcD</i> ^{VP} (S47K) R	GTTATCTTTTAGTGCTTTTACACCCTTGCCTATA GCTCCACAAAGACCAAT	This study
CMW3450	<i>avcD</i> ^{VP} (E376A) F	GAGAGCTGTACACGCAGCAATGGATGCCATTGT TG	This study
CMW3451	<i>avcD</i> ^{VP} (E376A) R	CAACAATGGCATCCATTGCTGCGTGTACAGCTC TC	This study
Gene Deletion			
CMW2794	ΔVSP-2 up ⁴ F; CR02 & CR03	GTGGAATTCCTGGGAGAGCTCGGCTTGTTCACT ATCGTAATAATGC	This study
CMW2795	ΔVSP-2 up R; CR02 & CR03	GGAGGGGCCACCACTGGGAGGGCACCAGATTC	This study
CMW2796	ΔVSP-2 down ⁵ F; CR02 & CR03	GCCCTCCAGTGGTGGCCCCTCCAGGT	This study

CMW2797	Δ VSP-2 down R; CR02 & CR03	AGCTATAGTTCTAGAGGTACGGGCATTAAGGTG GTGGAAACCG	This study
CMW2814	Δ VSP-1 up F; CR01 & CR03	GTGGAATTCCTGGGAGAGCTGGCTTTACTGTTA TTCGC	This study
CMW2815	Δ VSP-1 up R; CR01 & CR03	TACCATGTAGTAGCGGTATCGAGATTCC	This study
CMW2816	Δ VSP-1 down F; CR01 & CR03	GATACCGCTACTACATGGTAACGAACCTCTTC	This study
CMW2817	Δ VSP-1 down R; CR01 & CR03	AGCTATAGTTCTAGAGGTACCGCTAAGTTTGTG GATGC	This study
CMW2970	Δ vc0176 up F; BYH207	ATAACAATTTGTGGAATTCCTGGGAGAGCTGGG AATCGAATATTGAGAG	This study
CMW2971	Δ vc0176 up R; BYH207	ATATAGTGTCTCTATTTATGGCTCATAATCTTGA AG	This study
CMW2972	Δ vc0176 down F; BYH207	GATTATGAGCCATAAATAGAGACACTATATTTAG TGTTTAATTAAC	This study
CMW2973	Δ vc0176 down R; BYH207	TGCGCATGCTAGCTATAGTTCTAGAGGTACTAT GAACTTATTTCTATACTCTCAG	This study
CMW3067	Δ avcD up F; GS05	GTGGAATTCCTGGGAGAGCTACTATATTTAGTG TTTAATTAACAAAAAC	This study
CMW3068	Δ avcD up R; GS05	CAGACTAAAGCCTGAAATTATGAACTTATTTCT ATAC	This study
CMW3069	Δ avcD down F; GS05	TAATTTCAAGCTTTAGTCTGGAAAATTCACTTTT C	This study
CMW3070	Δ avcD down R; GS05	AGCTATAGTTCTAGAGGTACACATGGAGCATGA TCAGG	This study
CMW3071	Δ Ig ²²² up F; BYH206	ATAACAATTTGTGGAATTCCTGGGAGAGCTTCT CAAAGAAGCACGTAAAAAAG	This study
CMW3072	Δ Ig ²²² up R; BYH206	CAAGAATTAACGTGGTAAAGTGCGCACATTCTA C	This study
CMW3073	Δ Ig ²²² down F; BYH206	AATGTGCGCACTTTACCACGTTAATTCTTGATTA GC	This study
CMW3074	Δ Ig ²²² down R; BYH206	TGCGCATGCTAGCTATAGTTCTAGAGGTACTCA TTTTCTTCTGAGGTTTC	This study
qPCR			
CMW2926	<i>gyrA</i> F	TGGCCAGCCAGAGATCAAG	This study
CMW2927	<i>gyrA</i> R	ACCCGCAGCGGTACGA	This study
CMW3206	<i>avcD</i> F	TCGACCAGTTAAAGCACCT	This study
CMW3207	<i>avcD</i> R	CCTTCTGTACGGATCAAGCCA	This study
CMW3208	<i>avcI</i> F	GTGAATGGATATTTCCGGTGA	This study
CMW3209	<i>avcI</i> R	TTGTCGCTATTAGAAGCGTT	This study
CMW3288	<i>oril</i> F	CAGGTGAACCAGCAAATCGA	71
CMW3289	<i>oril</i> R	TGGTATTGAAGCTCAATGCGG	71
CMW3290	<i>terI</i> F	TTCAAGCTGAGGCGGATTTG	71
CMW3291	<i>terI</i> R	GCTCATTGGCTTCTTGCTT	71
In vitro Transcription Synthesis			
EJW002	<i>avcI</i> RNA F	GACCATGATTACGCCATAATACGACTCACT ATAGGGATGATTACAAGCATTTCATG	This study
EJW003	<i>avcI</i> RNA R	[mU][mU]ACCAATGGATTTTTTGTGC	This study
EJW016	<i>avcI</i> -RC RNA F	GACCATGATTACGCCATAATACGACTCACT ATAGGGTTACCAATGGATTTTTTG	This study


EJW017	<i>avcI</i> -RC RNA R	[mA][mU]GATTACAAGCATTG	This study
--------	-----------------------	------------------------	------------

- 260 ¹F = Forward
- 261 ²R= Reverse
- 262 ³RBS= Ribosomal Binding Site
- 263 ⁴Up= Amplifies Upstream Fragment
- 264 ⁵Down= Amplifies Downstream Fragment
- 265
- 266
- 267
- 268

269 **Supplementary Table 4:** Maximum conservation of homologs from different phylogenetic lineages.

AvcD homologs summary table		
Lineages and percentage similarities of AvcD homologs containing both DCD and PLN domains		
DomArch.Gene3D	Lineage	Max%Positive
PLN+DCD	Bacteria>Proteobacteria	100.00
PLN+DCD	Bacteria>Bacteroidetes	58.80
PLN+DCD	Bacteria>Balneolaeota	56.02
PLN+DCD	Bacteria>Actinobacteria	55.63
PLN+DCD	Archaea>Thaumarchaeota	53.65
PLN+DCD	Bacteria>Firmicutes	52.27
PLN+DCD	Bacteria>Planctomycetes	52.27
PLN+DCD	Bacteria	51.88
NABP+PLN+DCD	Bacteria>Proteobacteria	51.09
PLN+DCD	Bacteria>Acidobacteria	49.70
PLN+DCD	Bacteria>Verrucomicrobia	48.69
PLN+DCD	Bacteria>Chlamydiae	45.25
PLN+DCD+NABP	Bacteria>Proteobacteria	42.48
PLN+DCD+NABP+NABP	Bacteria>Proteobacteria	39.85
PLN+PLN+DCD	Bacteria>Proteobacteria	36.75
PLN+DCD	Bacteria>Cyanobacteria	34.63
PLN+DCD	Eukaryota>Ascomycota	27.63
PLN+DCD	Eukaryota>Ciliophora	27.57
PLN+DCD	Eukaryota>Basidiomycota	25.10
PLN+DCD	Eukaryota>Chytridiomycota	23.77
PLN+DCD	Eukaryota>Mucoromycota	22.63
PLN+DCD	Eukaryota>Apicomplexa	19.96
PLN+DCD	Eukaryota>Streptophyta	19.39
PLN+Znf_CCHC+DCD	Eukaryota>Ascomycota	16.92

Key
(% pos)



100
15

Abbreviations. PLN, P-loop containing nucleotide triphosphate hydrolases; DCD, Cytidine Deaminase domain 2; NABP, Nucleic acid-binding proteins; Znf_CCHC, Zinc finger CCHC-type

271
272

Supplementary Table 5: Absolute intracellular concentration of dNTPs from Figure 2E

Nucleotides	Absolute Intracellular dNTP Concentration in pmol/mg of Total Protein				
	pVector	pAvcD ^{WT}	pAvcD ^{S52K}	pAvcD ^{E384A}	pAvcD ^{ETEC}
dATP	37.8 ± 2.6	60.9 ± 9.1	32.3 ± 1.8	35.0 ± 2.9	29.5 ± 2.9
dCTP	33.2 ± 3.6	8.3 ± 1.5	28.9 ± 1.6	34.7 ± 3.7	11.8 ± 0.9
dGTP	213.4 ± 22.7	229.5 ± 69.6	178.5 ± 8.9	211.9 ± 18.4	163.9 ± 9.7
dTTP	57.1 ± 3.7	82.47 ± 23.3	44.9 ± 1.2	53.9 ± 2.1	51.9 ± 11.1
dUTP	5.4 ± 0.5	n.d.	4.7 ± 0.4	5.6 ± 0.5	n.d.
dCMP	3579.1 ± 1242.7	592.8 ± 113.9	3429.7 ± 1113.2	3513.9 ± 975.2	972.6 ± 318.1
dUMP	46.6 ± 14.5	35.4 ± 1.4	45.7 ± 16.5	43.5 ± 5.6	49.8 ± 16.3

273